

## **LALK Drug Backorder Memo**

To: All Providers

From: Pharmacy Department

Date: January 30, 2024

Drug Affected: Intravenous Linezolid (Zyvox)

Dear Providers,

Currently, there is a backorder of IV linezolid by multiple manufacturers for an unknown reason. At LALK, we have a limited stock, and the estimated release date of more vials from the manufacturer is undetermined making obtaining IV linezolid an ongoing problem.

Linezolid is an oxazolidinone antibiotic with activity against Gram-positive organisms, commonly used for methicillin-resistant *Staphylococcus aureus* (MRSA). Linezolid comes in both IV and PO, the PO formulation is 100% bioavailable making it a great option for non-severe MRSA infections.

Please consider alternative options while IV linezolid is on backorder if PO is not indicated. The following restriction criteria will be employed to reserve stock:

## **IV Linezolid Restriction**

## IV linezolid orders must meet one of the following:

- Patients in an ICU
- Ordering by ID physician
- Allergy to or failing alternative options (IV vancomycin or IV daptomycin)

If the order does not meet restriction criteria, a pharmacist will reach out to notify you and recommend alternative treatment options.

## For any questions/concerns, please contact:

Melanie Rae Schrack, PharmD, BCIDP Infectious Diseases Pharmacy Specialist Our Lady of the Lake Regional Medical Center 5000 Hennessy Blvd| Baton Rouge, LA 70808 E: melanie.schrack@fmolhs.org |P: 225-374-8768